Valuation: Avadel Pharmaceuticals plc

Market Cap 2.12B 1.86B 1.72B 1.58B 2.98B 204B 3.05B 20.45B 8.06B 100B 7.98B 7.8B 345B P/E 2024
-20.5x
P/E 2025 33.7x
Enterprise Value 2B 1.75B 1.61B 1.48B 2.8B 192B 2.86B 19.21B 7.58B 94.07B 7.49B 7.33B 324B EV / Sales 2024
5.78x
EV / Sales 2025 7.12x
Free-Float
99.5%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Avadel Pharmaceuticals plc

1 day+0.05%
6 months+0.74%
Current year+0.42%
Current year 21.4
Extreme 21.395
21.76
1 year 10.42
Extreme 10.42
23.57
3 years 6.38
Extreme 6.38
23.57
5 years 6.38
Extreme 6.38
23.57
10 years 6.38
Extreme 6.38
23.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2020-12-06
Chief Tech/Sci/R&D Officer - 2019-12-01
Investor Relations Contact - -
Date Insider Type Main position Quantity % Market Cap.
2/13/26
Weiss Asset Management LP
SellCompany 11,112,052 11.3600%
2/12/26 Issuer sale

Chief Financial Officer

1,104,900 1.1296%
2/12/26 Issuer sale

Chief Operating Officer

300,000 0.3067%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%-.--%+99.82% - 2.12B
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.06%+0.48%+35.66%+53.91% 357.72B
Weighted average by Cap. +0.37%+0.02%+37.55%+79.63%

Financials

2024 2025
Net sales 169M 148M 137M 126M 237M 16.28B 243M 1.63B 642M 7.97B 635M 621M 27.46B 279M 244M 225M 208M 391M 26.87B 401M 2.69B 1.06B 13.16B 1.05B 1.03B 45.33B
Net income -48.83M -42.73M -39.43M -36.33M -68.43M -4.7B -70.12M -470M -185M -2.3B -183M -179M -7.93B 64.67M 56.59M 52.22M 48.11M 90.62M 6.23B 92.86M 623M 246M 3.05B 243M 238M 10.5B
Net Debt -34.93M -30.57M -28.21M -25.99M -48.95M -3.36B -50.16M -336M -133M -1.65B -131M -128M -5.67B -129M -113M -104M -95.9M -181M -12.41B -185M -1.24B -489M -6.08B -484M -473M -20.93B
Logo Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Employees
188
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. AVDL Stock